The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).
"Chronic hepatitis delta is the most aggressive form of viral hepatitis and the lack of approved treatments in the United ...
A new study conducted during the first-ever reactive use of the Hecolin vaccine in South Sudan showed that a two-dose regimen ...
The company will use the funding to advance clinical trials for Tune-401, the epigenetic silencing drug for treating chronic ...
Having peers facilitate virtual visits may lead to many more patients with hepatitis C receiving treatment and clearing the ...
FDA tackles viral contamination in berries with new safety measures. Learn risks, prevention, and consumer tips for berry ...
The drug has been granted Breakthrough Therapy designation by the FDA for the treatment of chronic hepatitis delta (CHD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback